cefepime + zidebactam

Cefepime + zidebactam is a fixed-dose intravenous antibacterial combination marketed as **Zaynich**. It combines cefepime, a fourth-generation cephalosporin, with zidebactam, a beta-lactamase inhibitor and non-beta-lactam antibacterial beta-lactam enhancer. The agents act synergistically through complementary inhibition of bacterial penicillin-binding proteins, principally cefepime activity at PBP3 and high-affinity zidebactam activity at PBP2, with zidebactam also inhibiting susceptible serine beta-lactamases. In the United States, Zaynich was approved in 2026 for adult patients with complicated urinary tract infection, including pyelonephritis, caused by designated susceptible microorganisms. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220787Orig1s000lbl.pdf))

Brand names

Zaynich

Other names

FEP-ZIDZID-FEPcefepime-zidebactamcefepime/zidebactamzidebactam + cefepimezidebactam-cefepimezidebactam/cefepime